Iovance Biotherapeutics, Inc. (IOVA) Stock Price & Analysis
Iovance Biotherapeutics, Inc. (IOVA) fell 3.00% to USD 3.88 as of June 10, 2026 at 00:44 UTC, according to Nexqual real-time market data.
IOVA last closed at USD 4; the session ranged USD 3.77–4.13 on volume of 11,189,435 shares. Market capitalization is $1.73B, with a 52-week range of USD 1.66–5.63 (NGM). Source: Nexqual, June 10, 2026 at 00:44 UTC.
Key Statistics (as of June 10, 2026 at 00:44 UTC)
| Price | USD 3.88 |
|---|---|
| Change | ▼ 3.00% (down) |
| Previous Close | USD 4 |
| Open | USD 4.09 |
| Day Range | USD 3.77 – 4.13 |
| 52-Week Range | USD 1.66 – 5.63 |
| Volume | 11,189,435 shares |
| Market Cap | $1.73B |
| Exchange | NGM |
Technical Analysis (IOVA)
Nexqual's technical model rates IOVA "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:44 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 50.35 (neutral) |
| vs SMA50 | Above (USD 3.71) |
| MACD | 0.11 (positive) |
Analyst Ratings (IOVA)
Wall Street analysts rate IOVA "Buy" based on 10 analysts, with a mean price target of USD 8.8 (range USD 4–14), per Nexqual as of June 10, 2026 at 00:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 8.8 |
| High Target | USD 14 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 8 / 2 / 0 |
Earnings (IOVA)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $87.76M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.19 vs est -0.15 ▼ miss |
| 2025-12-31 | USD -0.18 vs est -0.18 ▼ miss |
| 2025-09-30 | USD -0.25 vs est -0.26 ▲ beat |
| 2025-06-30 | USD -0.33 vs est -0.28 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Financials & Fundamentals (IOVA)
| Total Revenue | $285.61M |
|---|---|
| Revenue Growth (YoY) | +44.80% |
| Gross Margin | +39.44% |
| Operating Margin | -113.46% |
| Profit Margin | -123.90% |
| ROE | -47.51% |
| Debt / Equity | 6.62 |
| Current Ratio | 3.61 |
| Total Cash | $313.44M |
| Total Debt | $47.78M |
| Free Cash Flow | $-149.07M |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Financial Health Score (IOVA)
Nexqual rates Iovance Biotherapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:44 UTC.
| Growth | Strong — Revenue +61% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $313M cash vs $48M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$149M, burning cash |
| Efficiency | Critical — ROE -48%, ROA -23.6% |
Ownership (IOVA)
| Insider Ownership | +0.33% |
|---|---|
| Institutional Ownership | +67.47% |
| Shares Outstanding | 446.50M |
| Float | 387.95M |
| Short % of Float | +25.56% |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Leadership (IOVA)
Iovance Biotherapeutics, Inc. is led by Frederick G. Vogt Esq. (age 51), Interim CEO, President, General Counsel, Corporate Secretary & Director, per Nexqual as of June 10, 2026 at 00:44 UTC.
| Interim CEO, President, General Counsel, Corporate Secretary & Director | Frederick G. Vogt Esq. (age 51) |
|---|---|
| Chief Financial Officer | Corleen M. Roche (age 59) |
| Chief Operating Officer | Igor P. Bilinsky (age 52) |
| Senior Vice President of Investor Relations & Corporate Communications | Sara Pellegrino |
| Executive Vice President of Human Resources | Tracy Winton |
Major Backers & Investors (IOVA)
Notable institutional backers of Iovance Biotherapeutics, Inc. include MHR Fund Management, LLC, Two Sigma Investments, LP, Millennium Management, according to Nexqual as of June 10, 2026 at 00:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MHR Fund Management, LLC | 6.49% |
| Two Sigma Investments, LP | 3.07% |
| Millennium Management | 2.11% |
| Goldman Sachs | 1.96% |
| Invenomic Capital Management, LP | 1.9% |
| NORTHERN LIGHTS FUND TRUST II-Invenomic Fund | 1.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.61% |
| BlackRock | 9.95% |
| State Street | 5.95% |
| Geode Capital | 1.92% |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
From Iovance Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
- The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
- The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FATE | Fate Therapeutics, Inc. | USD 1.9 | ▼ 4.04% |
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
| NTLA | Intellia Therapeutics, Inc. | USD 12.89 | ▼ 4.8% |
| TGTX | TG Therapeutics, Inc. | USD 43.37 | ▲ 7.99% |
| CDNA | CareDx, Inc. | USD 22.75 | ▲ 2.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:44 UTC. This page is informational and not investment advice.